Literature DB >> 25218973

Mapping the interaction site for the tarantula toxin hainantoxin-IV (β-TRTX-Hn2a) in the voltage sensor module of domain II of voltage-gated sodium channels.

Tianfu Cai1, Ji Luo1, Er Meng2, Jiuping Ding3, Songping Liang1, Sheng Wang4, Zhonghua Liu5.   

Abstract

Peptide toxins often have pharmacological applications and are powerful tools for investigating the structure-function relationships of voltage-gated sodium channels (VGSCs). Although a group of potential VGSC inhibitors have been reported from tarantula venoms, little is known about the mechanism of their interaction with VGSCs. In this study, we showed that hainantoxin-IV (β-TRTX-Hn2a, HNTX-IV in brief), a 35-residue peptide from Ornithoctonus hainana venom, preferentially inhibited rNav1.2, rNav1.3 and hNav1.7 compared with rNav1.4 and hNav1.5. hNav1.7 was the most sensitive to HNTX-IV (IC50∼21nM). In contrast to many other tarantula toxins that affect VGSCs, HNTX-IV at subsaturating concentrations did not alter activation and inactivation kinetics in the physiological range of voltages, while very large depolarization above +70mV could partially activate toxin-bound hNav1.7 channel, indicating that HNTX-IV acts as a gating modifier rather than a pore blocker. Site-directed mutagenesis indicated that the toxin bound to site 4, which was located on the extracellular S3-S4 linker of hNav1.7 domain II. Mutants E753Q, D816N and E818Q of hNav1.7 decreased toxin affinity for hNav1.7 by 2.0-, 3.3- and 130-fold, respectively. In silico docking indicated that a three-toed claw substructure formed by residues with close contacts in the interface between HNTX-IV and hNav1.7 domain II stabilized the toxin-channel complex, impeding movement of the domain II voltage sensor and inhibiting hNav1.7 activation. Our data provide structural details for structure-based drug design and a useful template for the design of highly selective inhibitors of a specific subtype of VGSCs.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nav1.7; Tarantula toxin; VGSCs; Voltage sensor

Mesh:

Substances:

Year:  2014        PMID: 25218973     DOI: 10.1016/j.peptides.2014.09.005

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  17 in total

1.  Gating modifier toxins isolated from spider venom: Modulation of voltage-gated sodium channels and the role of lipid membranes.

Authors:  Akello J Agwa; Steve Peigneur; Chun Yuen Chow; Nicole Lawrence; David J Craik; Jan Tytgat; Glenn F King; Sónia Troeira Henriques; Christina I Schroeder
Journal:  J Biol Chem       Date:  2018-04-27       Impact factor: 5.157

Review 2.  Sodium channels and pain: from toxins to therapies.

Authors:  Fernanda C Cardoso; Richard J Lewis
Journal:  Br J Pharmacol       Date:  2017-09-02       Impact factor: 8.739

3.  Manipulation of a spider peptide toxin alters its affinity for lipid bilayers and potency and selectivity for voltage-gated sodium channel subtype 1.7.

Authors:  Akello J Agwa; Poanna Tran; Alexander Mueller; Hue N T Tran; Jennifer R Deuis; Mathilde R Israel; Kirsten L McMahon; David J Craik; Irina Vetter; Christina I Schroeder
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

4.  From identification to functional characterization of cyriotoxin-1a, an antinociceptive toxin from the spider Cyriopagopus schioedtei.

Authors:  Tânia C Gonçalves; Evelyne Benoit; Michael Kurz; Laetitia Lucarain; Sophie Fouconnier; Stéphanie Combemale; Lucie Jaquillard; Brigitte Schombert; Jean-Marie Chambard; Rachid Boukaiba; Gerhard Hessler; Andrees Bohme; Laurent Bialy; Stéphane Hourcade; Rémy Béroud; Michel De Waard; Denis Servent; Michel Partiseti
Journal:  Br J Pharmacol       Date:  2019-04-09       Impact factor: 8.739

5.  Venom-Derived Peptides Inhibiting Voltage-Gated Sodium and Calcium Channels in Mammalian Sensory Neurons.

Authors:  Arsalan Yousuf; Mahsa Sadeghi; David J Adams
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Engineering Highly Potent and Selective Microproteins against Nav1.7 Sodium Channel for Treatment of Pain.

Authors:  Anatoly Shcherbatko; Andrea Rossi; Davide Foletti; Guoyun Zhu; Oren Bogin; Meritxell Galindo Casas; Mathias Rickert; Adela Hasa-Moreno; Victor Bartsevich; Andreas Crameri; Alexander R Steiner; Robert Henningsen; Avinash Gill; Jaume Pons; David L Shelton; Arvind Rajpal; Pavel Strop
Journal:  J Biol Chem       Date:  2016-04-22       Impact factor: 5.157

7.  µ-TRTX-Ca1a: a novel neurotoxin from Cyriopagopus albostriatus with analgesic effects.

Authors:  Yun-Xiao Zhang; De-Zheng Peng; Qing-Feng Zhang; Biao Huang; Qiu-Chu Yang; Dong-Fang Tang; Min-Zhi Chen; Ming-Qiang Rong; Zhong-Hua Liu
Journal:  Acta Pharmacol Sin       Date:  2018-10-31       Impact factor: 6.150

8.  Structural Basis for High-Affinity Trapping of the NaV1.7 Channel in Its Resting State by Tarantula Toxin.

Authors:  Goragot Wisedchaisri; Lige Tonggu; Tamer M Gamal El-Din; Eedann McCord; Ning Zheng; William A Catterall
Journal:  Mol Cell       Date:  2020-11-23       Impact factor: 17.970

9.  The tarantula toxin β/δ-TRTX-Pre1a highlights the importance of the S1-S2 voltage-sensor region for sodium channel subtype selectivity.

Authors:  Joshua S Wingerd; Christine A Mozar; Christine A Ussing; Swetha S Murali; Yanni K-Y Chin; Ben Cristofori-Armstrong; Thomas Durek; John Gilchrist; Christopher W Vaughan; Frank Bosmans; David J Adams; Richard J Lewis; Paul F Alewood; Mehdi Mobli; Macdonald J Christie; Lachlan D Rash
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

10.  Spider toxin inhibits gating pore currents underlying periodic paralysis.

Authors:  Roope Männikkö; Zakhar O Shenkarev; Michael G Thor; Antonina A Berkut; Mikhail Yu Myshkin; Alexander S Paramonov; Dmitrii S Kulbatskii; Dmitry A Kuzmin; Marisol Sampedro Castañeda; Louise King; Emma R Wilson; Ekaterina N Lyukmanova; Mikhail P Kirpichnikov; Stephanie Schorge; Frank Bosmans; Michael G Hanna; Dimitri M Kullmann; Alexander A Vassilevski
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.